Akebia Therapeutics Inc.
NASDAQ:AKBA 4:00:00 PM EDT
| Market Cap (Intraday) | 286.84M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $1.41 |
| 50-Day MA | $1.58 |
| 200-Day MA | $1.32 |
Akebia Therapeutics Inc. Stock, NASDAQ:AKBA
245 First Street, Suite 1400, Cambridge, Massachusetts 02142
United States of America
Phone: +1.617.871.2098
Number of Employees: 167
Description
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.